Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
Drug Levels and Effects
Summary of Use during Lactation
Tinzaparin is no longer available in the US. Although tinzaparin has not been studied, other low molecular weight heparins (e.g., dalteparin, enoxaparin) are not excreted into breastmilk in clinically relevant amounts. Tinzaparin is acceptable to use during breastfeeding.[1]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Acenocoumarol, Dalteparin, Enoxaparin, Heparin, Rivaroxaban, Warfarin
References
- 1.
- Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317–59. [PMC free article: PMC6258928] [PubMed: 30482767]
Substance Identification
Substance Name
Tinzaparin
Drug Class
Breast Feeding
Lactation
Anticoagulants
Low Molecular Weight Heparin
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.